Surmodics, Inc. (Nasdaq: SRDX), a provider of medical device and in vitro diagnostic technologies to the healthcare industry, ...
The regulator says the proposed merger would give the combined company more than 50% of the market for a type of medical ...
The agency is challenging the deal, citing antitrust concerns due to GTCR's existing ownership of Surmodics' rival Biocoat.
The Federal Trade Commission sued Thursday to block private equity firm GTCR BC Holdings’ acquisition of Surmodics Inc., ...
The FTC has blocked GTCR's $627M acquisition of SRDX, citing anti-competitive concerns. Surmodics has responded to the challenge and plans to fight the decision in court.
The U.S. Federal Trade Commission (FTC) has filed a lawsuit to prevent medical device coatings maker Surmodics from merging ...
The Federal Trade Commission on March 6 sued to block GTCR’ s acquisition of Surmodics, alleging that “the deal, which seeks to combine the two largest manufacturers of critical medical device ...
The FTC said merging Surmodics with Biocoat, where GTCR has a majority stake, would result in one company with more than 50% ...
The U.S. Federal Trade Commission sued on Thursday to block medical device coatings maker Surmodics' acquisition by private ...
Surmodics stock drops 4.76% in premarket trading following news that the FTC will challenge its proposed acquisition by GTCR.
FTC files lawsuit to block Surmodics' $627M GTCR sale. Learn about the implications of this decision and its impact on SRDX.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback